Screener
Vor Biopharma VOR Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable | $1,043 | $5,127 |
| Accrued liabilities | 14,727 | 19,764 |
| Operating lease liabilities | 307 | 280 |
| Total current liabilities | 16,077 | 25,171 |
| Non-current liabilities: | ||
| Operating lease liabilities, less current portion | 2,632 | 2,720 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's accrued expenses?
- Vor Biopharma (VOR) reported accrued expenses of $14.73M in Q1 2026.
- How has Vor Biopharma's accrued expenses changed year-over-year?
- Vor Biopharma's accrued expenses increased by 33370.5% year-over-year, from $44K to $14.73M.
- What is the long-term trend for Vor Biopharma's accrued expenses?
- Over 5 years (2020 to 2025), Vor Biopharma's accrued expenses has grown at a 93.8% compound annual growth rate (CAGR), from $723K to $19.76M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Vor Biopharma's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude